The purpose of this project is to design and test in preclinical studies a new vaccine against SARS-CoV2. The overall objective: 1. In a first step, to test a new mRNA vaccine candidate encoding SARS-CoV2 epitopes selected through a bioinformatic approach and co-formulated with nanoparticles (mRNA-CoV2) in vitro and in vivo to assess the potential to induce SARS-CoV2-specific immune responses. 2. In a second step, to test if a prime-boost strategy with mRNA-CoV2 prime and MVA-CoV2 boost induce higher immune responses as compared with mRNA-CoV2 alone.
vacuna
RNAm
ARNm
epítopos SARS-CoV-2
bioinformática
nanopartículas
respuesta inmunitaria
COVID-19
SARS-CoV-2
Acción Estratégica en Salud (AES)
30/10/2021 - 31/01/2022
FELIPE GARCIA ALCAIDE
INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
INSTITUTO DE INVESTIGACIONES BIOMEDICAS AUGUST PI I SUNYER (IDIBAPS)
CATALUÑA
BARCELONA
550,000 €